Citations

Clear

171 citation(s) found for "Lipton, RB".

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program
Aurora, SK, Diener, HC, DeGryse, Ronald E., Turkel, Catherine C., Silberstein, Stephen D., Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Acta Neurologica Scandinavica | October 11, 2013 | Volume: 129 | Issue: 1 | Pages: 61-70

10.1111/ane.12171 | PMID 24107267 Get It

Migraine headache is present in the aura phase
Hansen, Jakob Møller , Silberstein, Stephen D., Saper, Joel R., Aurora, Sheena K. , Goadsby, Peter J. , Charles, Andrew , Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J , Charles, Andrew

Mayo Clinic

Neurology | November 1, 2012 | Volume: 79 | Issue: 20 | Pages: 2044-2049

10.1212/wnl.0b013e3182749eed | PMID 23115208 Get It

A self-administered screener for migraine in primary care
Lipton, R.B. , Sadovsky, Richard, Kolodner, Ken, Hettiarachchi, J. , Dodick, David W. , Endicott, Jane , Harrison, William James

Mayo Clinic

Neurology | May 14, 2012 | Volume: 61 | Issue: 3 | Pages: 375-382

10.1212/01.wnl.0000078940.53438.83 | PMID 12913201 Get It

Migraine practice patterns among neurologists
Bigal, ME, Rush, Steven R., Yenkosky, J. P., Liberman, Joshua N. , Bartleson, J. D., Silberstein, Stephen D., Lipton, Richard B.

Mayo Clinic

Neurology | May 14, 2012 | Volume: 62 | Issue: 11 | Pages: 1926-1931

10.1212/wnl.62.11.1926 | PMID 15184590 Get It

Validity of clinical criteria for the diagnosis of dementia with Lewy bodies
Verghese, Joe , Crystal, Howard, Dickson, Dennis W. , Lipton, Richard B.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 53 | Issue: 9 | Pages: 1974-1974

10.1212/wnl.53.9.1974 | PMID 10599768 Get It

Neurologic Munchausen's redux
Folger, W. Neath, Rovner, Richard N., Harter, Donald H., Lipton, Richard B. , Rn, Rovner

Mayo Clinic

Neurology | May 13, 2012 | Volume: 32 | Issue: 2 | Pages: 216

10.1212/wnl.32.2.216-a Get It

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine
Varon, SF, Grosberg, Brian M. , McAllister, Peter J., Freitag, F. G., Aurora, SK, Silberstein, Stephen D., DeGryse, Ronald E., Nolan, Marissa E., Turkel, Catherine C., Lipton, Richard B. , Dodick, David W. , Diener, Hans‐Christoph

Mayo Clinic

Neurology | September 29, 2011 | Volume: 77 | Issue: 15 | Pages: 1465-1472

10.1212/wnl.0b013e318232ab65 | PMID 21956721 Get It

P2‐128: Vascular and Alzheimer's Disease pathologies in relation to cognitive decline: Data from the Einstein Aging Study Autopsy series
Wang, Cuiling , Strozyk, Dorothea, Verghese, Joe , Katz, Mindy J. , Derby, Carol A. , Strozyk, Dorothea, Dickson, Dennis W. , Lipton, Richard B.

Mayo Clinic

Alzheimer's & Dementia | August 1, 2011 | Volume: 7 | Issue: 4S_Part_10 | Pages: No page available

10.1016/j.jalz.2011.05.1016 Get It

Serum biomarker analysis in a phase II study of irinotecan in refractory metastatic breast cancer (MBC).
Moreno‐Aspitia, Alvaro , Anderson, KS, Reinholz, MM, Lipton, A., Carney, W. P., Dueck, A. C. , Lafky, JM, Fitch, TR, Hillman, DW, Perez, EA, Lafky, Jacqueline M., Hillman, David W.

Mayo Clinic

Cancer Research | December 30, 2010 | Volume: 69 | Issue: 2_Supplement | Pages: 6074

10.1158/0008-5472.sabcs-6074 Get It

Abstract Abstract #6074 Objective: To analyze blood-serum biomarkers (HER2, EGFR, uPA, and TIMP-1) for prediction of response to treatment in conjunction with Study 96-32-55, a multicenter phase II trial assessing the efficacy and tolerability of two irinotecan schedules in anthracycline- or taxane-refractory MBC patients.
 Methods: MBC patients who experienced disease progression after one to three chemotherapy regimens, including at least one anthracycline- or taxane-based regimen, were randomly assigned to irinotecan in 6-week cycles comprising 100 mg/m2 weekly for 4 weeks, then a 2-week rest or 240 mg/m2 every 3 weeks. During this study the serum samples from each patient were collected at a possibility of three time points; prior to treatment, at the first occurrence of response, and at completion of or withdrawal from treatment. Response prediction was analyzed using predetermined elevated/non-elevated serum biomarker cutoffs. Percentage changes from baseline to first response and disease progression were analyzed.
 Results: In the weekly arm, the objective response (CR+PR) rate was 23% (95% CI, 13% to 37%), and in the every-3-weeks arm, the objective response rate was 14% (95% CI, 6% to 26%). Serum biomarker levels were determined for HER2, EGFR, uPA, and TIMP-1 prior to treatment for 91 patients. Of these 91 patients, 17 had serum measurements at first response, and 38 had serum measurements at their completion of study due to disease progression. Only 7 patients had serum-levels collected at all three event-points. The baseline levels of sHER2, EGFR, uPA, and TIMP-1 were not different among responders and non-responders (Fisher's Exact p=0.41, 0.26, 0.68, 0.75). sHER2 level increased by 20.6% from baseline to disease progression (p=0.01). TIMP-1 level was 15.2% lower than baseline at first response (p=0.03), 16.5% higher than baseline at disease progression (p=0.01), and for 7 patients with all three event-point measures, TIMP-1 was 21.8% lower than baseline at first response and was 22.3% higher than baseline at disease progression (p=0.02, 0.04).
 Conclusions: In this study, serum levels of HER2, EGFR, uPA, and TIMP-1 do not appear to be predictive of response. However, interpretation of the data is compromised due to limited availability of serum at all 3 points. Serum HER2 appears higher at disease progression than at baseline. Serum TIMP-1 appears to decrease from baseline to first response, and then appears to increase at disease progression. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6074.
Topiramate intervention to prevent transformation of episodic migraine: The topiramate INTREPID study
Silberstein, Stephen D., Cady, Roger , Freitag, Fred, Mathew, Ninan T., Biondi, David M., Ascher, Steven, Olson, William H., Hulihan, Joseph, Lipton, Richard B. , Dodick, David W.

Mayo Clinic

Cephalalgia | May 17, 2010 | Volume: 31 | Issue: 1 | Pages: 18-30

10.1177/0333102410372427 | PMID 20974598 Get It

Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9–14 migraine headache days/month). A secondary objective was to assess the efficacy of topiramate as preventive migraine treatment in this population. Methods: This was a multicenter, randomized, double-blind, placebo-controlled study comparing topiramate 100 mg/day and placebo for 26 weeks. The primary efficacy variable was new-onset CDH at month 6. Secondary efficacy measures included migraine and headache days. Adverse events (AEs) were evaluated. Results: A total of 159 topiramate subjects and 171 placebo subjects were efficacy-evaluable. At month 6, 1.4% of topiramate subjects versus 2.3% of placebo subjects had CDH ( p = .589). Compared with placebo, topiramate treatment was associated with statistically significant reductions in mean number of migraine days (6.6 vs. 5.3/28 days; p = .001) and headache days (6.6 vs 5.3/28 days; p = .001). Most commonly reported AEs in the topiramate versus placebo group included paresthesia (32.4% vs. 7.0%), fatigue (14.8% vs. 8.6%), dizziness (11.4% vs. 7.6%) and nausea (10.8% vs. 9.2%). Conclusion: Topiramate 100 mg/day did not prevent the development of CDH at six months in subjects with HFEM. Topiramate was effective in reducing headache days and migraine headache days and generally well tolerated.